{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-003165","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.347489+00:00","generated_at":"2026-05-15T07:42:05.758641+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled","bullets":["Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.","NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.","NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.","PIPE financing anchored by $10M commitment from Cinctive Capital Management.","Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-003165","json":"https://secwatch.observer/filing/0001829126-26-003165.json","markdown":"https://secwatch.observer/filing/0001829126-26-003165.md","text":"https://secwatch.observer/filing/0001829126-26-003165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/0001829126-26-003165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:42:05.758641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2262c7a90c5c2f5b3135a90de354d47f4c0782ac","claim":"NEONC TECHNOLOGIES HOLDINGS, INC. reported the quarter and year ended December 31, 2025 results: net income $62.1 million or $3.20 per diluted share, EPS $3.20 per diluted share.","evidence_excerpt":"$3,045k in Q4 2024, driven by active management of NEO100 trial sites, recruitment for NEO212, initiation of NEO100-3, and overall patient recruitment activity. ● Net loss: $62.1 million or $3.20 per diluted share, compared to $11.9 million or $0.69 per diluted share in Q4 2024, primarily due to increased general and administrative expenses, as well as","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626003165/0001829126-26-003165-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2025"},{"label":"Net income","value":"$62.1 million or $3.20 per diluted share"},{"label":"EPS","value":"$3.20 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}